United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

MAINZ, Germany and NEW YORK, July  20, 2020  (GLOBE NEWSWIRE) --  BioNTech SE  (Nasdaq: BNTX, “BioNTech” or “the Company”) and  Pfizer Inc . (NYSE: PFE) today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. The data are available on an online preprint server at  medRxiv  and are concurrently undergoing scientific peer-review for potential publication.

Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

An effective vaccine is yet to be proven, however the U.K. has now secured access to up to 230 million vaccine doses.

Britain Secures 90 Million Doses Of Potential Coronavirus Vaccines From Pfizer, BioNTech & Valneva

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval.

Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2

AstraZeneca

Moderna

Novavax

GlaxoSmithKline

Inovio Pharmaceuticals

Sinovac Biotech

Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.

Here Are All the COVID-19 Vaccines Currently in Clinical Testing

The 1 Number Healthcare Investors Should Consider When a Company Releases Study Results

A coronavirus vaccine has the potential to not only save countless lives, but also to mitigate trillions in economic damage.

Which Biotech Company Has the Most Promising Coronavirus Vaccine?

Gilead Sciences

The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy.

BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies

Chevron

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walgreens

Exxon Mobil

Experienced dividend investors know that sometimes a high yield is a red flag.

6 Dow Stocks With Yields of 4%+

Regeneron Pharmaceuticals

Dozens are racing to develop a vaccine that could end the COVID-19 pandemic; so far, these companies look most likely to succeed.

4 Coronavirus Stocks to Watch This Summer

Quest Diagnostics

Labcorp Holdings Inc

Sanofi

COVID-19 crushed the stock market in March. The only real survivors were companies involved with testing, treatments and vaccines.

8 Coronavirus Stocks That Can Deliver Even More Upside Ahead

AbbVie

Bristol-Myers

And they each offer great dividends, too.

These 3 Stocks Are Still Ridiculously Cheap Right Now

Bausch Health Companies Inc

Johnson & Johnson

Author Gerald Posner discusses his latest book, a history of the pharmaceutical industry.

Capital Interviews: Gerald Posner Discusses His New Book On Pharma, The Pandemic, And The Future Of The Industry

Bloomin' Brands

Denny's

Brinker International

Ruth's Hospitality Group

Chains such as Outback Steakhouse, Chili's, Denny's, and Ruth's Chris were climbing on a positive vaccine trial.

Why Casual Dining Restaurant Stocks Were Gaining Today

Eli Lilly

After a few years hanging out quietly on the sidelines, the Health Care sector roared back to prominence this year as COVID-19 ravaged the globe. Suddenly, vaccines and antibodies catapulted into the headlines, drawing attention to biotech and pharma amid a race to treat or prevent the virus.

GILDing” The Lilly: Vaccines, Treatments For Virus In Spotlight Ahead Of Health Care Q2 Earnings

As investors cheer signs of progress in COVID-19 vaccine development, here're three stocks that are worth keeping an eye on.

Markets Bet Big on Coronavirus Vaccine Stocks: 3 Front Runners

Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.

Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress

Pfizer's (PFE) shares jump after FDA grants fast track status to two coronavirus vaccine candidates

Pfizer/BioNTech's Coronavirus Vaccine Gets FDA Fast Track Tag

Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.

Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight

Abbott Labs

Merck

Large drugmakers are hoping to stop a looming global crisis that could be much worse than COVID-19.

Why Big Pharma's $1 Billion Bet to Prevent a Bacterial Pandemic Matters for You

BioCryst Pharmaceuticals

Biosig Technologies Inc

CytoDyn Inc.

Eiger BioPharmaceuticals

Immunic Inc

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Antivirals In The COVID-19 Space

The companies expect to manufacture 100 million doses by the end of 2021.

Pfizer and BioNTech Get "Fast Track" Designation for 2 COVID-19 Vaccines

Bank of America

Federal Realty Investment Trust

Altria

While some planning is required to successfully invest in dividend stocks, taking action to get started is just as important.

10 All Weather Dividend Stocks To Get You Started

News for Pfizer Stock (PFE)